How well does LIBTAYO(Lebrikizumab) work?

LIBTAYO functions as an immune checkpoint inhibitor to enhance anti-tumor immune responses, specifically in advanced CSCC patients.

Therapeutic Effect of LIBTAYO

LIBTAYO is a programmed cell death protein-1 (PD-1) inhibitor that improves immune system activity against cancer cells by blocking the PD-1 receptor, which typically suppresses immune responses. Its therapeutic effect is particularly evident in patients with metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC) who cannot undergo curative surgery or radiation. By stimulating T-cells to attack tumor cells, LIBTAYO offers a promising treatment for advanced CSCC, which is otherwise challenging to manage with conventional therapies. Its role in other cancers or broader immune-oncology treatments is not specified in the description.